bioRxivCancer Biology
SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes
J. L. Manley, Y. K. Lieu, Z. Liu, X. Wei, A. Penson, J. Zhang, X. An, R. Rabadan, A. Raza, S. Mukherjee
Abstract
ABSTRACTSF3B1 is the most frequently mutated RNA splicing factor in multiple neoplasms, including ~25% of myelodysplastic syndromes (MDS) patients. Mortality in MDS frequently results from severe anemia, but the underlying mechanism is largely unknown. Here we elucidate the detailed, elusive pathway by which SF3B1 mutations cause anemia. We demonstrate, in CRISPR-edited cell models, normal human primary cells, and MDS patient cells, that mutant SF3B1 induces a splicing error in transcripts encoding the kinase MAP3K7, resulting in reduced MAP3K7 protein levels and deactivation of downstream target p38 MAPK. We show that disruption of this MAP3K7-p38 MAPK pathway leads to premature downregulation of GATA1, a master regulator of erythroid differentiation, and that this is sufficient to trigger accelerated differentiation and apoptosis. As a result, the overproduced, late staged erythroblasts undergo apoptosis and are unable to mature in the bone marrow. Our findings provide a detailed mechanism explaining the origins of anemia in MDS patients harboring SF3B1 mutations.Competing Interest StatementThe authors have declared no competing interest.View Full Text
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Erythroid differentiation intensifies RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts
P. L. Moura, T. Mortera-Blanco, … E. Hellstrom-Lindberg·bioRxiv·Apr 11, 2023
- SF3B1-mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition
Jonas Thier, Sophia Hofmann, … Vanessa Lundin·LeukemiaPeer-reviewed·Aug 26, 2025
- CDK8 is a critical effector of cell fate dysregulation in SF3B1-mutant MDS
Elizabeth A. Bonner, Tun‐Yun Hsueh, … Stanley Chun-Wei Lee·bioRxiv·Aug 14, 2025
- Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes
R. Kanagal-Shamanna, G. Montalban-Bravo, … G. Garcia-Manero·bioRxiv·Sep 4, 2020
- Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutations
G. Choudhary, A. Pellagatti, … A. Verma·bioRxiv·Mar 9, 2022
- IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes
V. Adema, I. Ganan-Gomez, … S. Colla·bioRxiv·Sep 28, 2023